Hunter disease before and during enzyme replacement therapy

Pediatric Neurology

Volumn 45, Issue 3, 2011, Pages 181-184

  Hoffmann, Björn ^a,b   Schulze Frenking, Gudrun ^c   Al Sawaf, Sulaiman ^a   Beck, Michael ^c   Mayatepek, Ertan ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Children's Hospital   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLEMASTINE; IDURONATE 2 SULFATASE; PREDNISOLONE; RANITIDINE;

ADULT; ARTICLE; BODY HEIGHT; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FRAMESHIFT MUTATION; GASTROINTESTINAL TRACT FUNCTION; GENETIC ANALYSIS; HUMAN; HUNTER SYNDROME; MALE; MISSENSE MUTATION; MOLECULAR GENETICS; NEUROLOGIC DISEASE; PHENOTYPE; PHYSICAL CAPACITY; PRIORITY JOURNAL; SCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION; VISCERA; VISCERAL LARVA MIGRANS SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; GASTROINTESTINAL TRACT; GLYCOSAMINOGLYCANS; HUMANS; IDURONATE SULFATASE; INFANT; INFANT, NEWBORN; MALE; MUCOPOLYSACCHARIDOSIS II; NERVOUS SYSTEM DISEASES; ORGAN SIZE; YOUNG ADULT;

EID: 80051523644     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2011.05.010     Document Type: Article

References (13)

1. F. Baehner, C. Schmiedeskamp, and F. Krummenauer Cumulative incidence rates of the mucopolysaccharidoses in Germany J Inherit Metab Dis 28 2005 1011 1017 (Pubitemid 43168938)
2. J. Nelson, J. Crowhurst, B. Carey, and L. Greed Incidence of the mucopolysaccharidoses in Western Australia Am J Med Genet [A] 123A 2003 310 313 (Pubitemid 37464354)
3. J. Muenzer, J.C. Lamsa, A. Garcia, J. Dacosta, J. Garcia, and D.A. Treco Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): A preliminary report Acta Paediatr Scand 91 Suppl 2002 98 99 (Pubitemid 36174159)
4. J. Muenzer, M. Gucsavas-Calikoglu, S.E. McCandless, T.J. Schuetz, and A. Kimura A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome) Mol Genet Metab 90 2007 329 337 (Pubitemid 46241902)
5. J. Muenzer, J.E. Wraith, and M. Beck A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet Med 8 2006 465 473
6. J. Muenzer, M. Beck, and C.M. Eng Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Genet Med 13 2011 95 101
7. J. Muenzer, M. Beck, and R. Giugliani Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey Genet Med 13 2011 102 109
8. G. Souillet, N. Guffon, and I. Maire Outcome of 27 p.tients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources Bone Marrow Transplant 31 2003 1105 1117 (Pubitemid 36857368)
9. J.S. Weisstein, E. Delgado, L.S. Steinbach, K. Hart, and S. Packman Musculoskeletal manifestations of Hurler syndrome: Long-term follow-up after bone marrow transplantation J Pediatr Orthop 24 2004 97 101 (Pubitemid 38030056)
10. B. Hoffmann, M. Schwarz, A. Mehta, and S. Keshav Gastrointestinal symptoms in 342 patients with Fabry disease: Prevalence and response to enzyme replacement therapy Clin Gastroenterol Hepatol 5 2007 1447 1453 (Pubitemid 350181595)
11. K. Sukegawa-Hayasaka, Z. Kato, and H. Nakamura Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: Enzymatic activity, protein processing and structural analysis J Inherit Metab Dis 29 2006 755 761 (Pubitemid 44756394)
12. M. Rathmann, S. Bunge, M. Beck, H. Kresse, A. Tylki-Szymanska, and A. Gal Mucopolysaccharidosis type II (Hunter syndrome): Mutation "hot spots" in the iduronate-2-sulfatase gene Am J Hum Genet 59 1996 1202 1209 (Pubitemid 26394111)
13. E. Glamuzina, E. Fettes, and K. Bainbridge Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: The relevance of clinical trial end points J Inherit Metab Dis 34 2011 749 754